Financials Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-10-11 pm EDT			5-day change	1st Jan Change
52.20 ^USD	-0.38%		-3.26%	+1.73%

Oct. 09	UBS Adjusts Price Target on Bristol-Myers Squibb to $54 From $50, Maintains Neutral Rating	MT
Oct. 08	CytoDyn Appoints Max Lataillade as Senior Vice President and Head of Clinical Development	CI

Projected Income Statement: Bristol-Myers Squibb Company

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	26,145	42,518	46,385	46,159	45,006	46,768	46,496	44,053
Change	-	62.62%	9.09%	-0.49%	-2.5%	3.92%	-0.58%	-5.26%
EBITDA ¹	9,945	18,118	20,493	20,123	17,498	5,068	17,936	15,842
Change	-	82.18%	13.11%	-1.81%	-13.04%	-71.04%	253.91%	-11.68%
EBIT ¹	8,199	17,426	19,830	19,442	16,785	4,498	16,941	15,579
Change	-	112.54%	13.8%	-1.96%	-13.67%	-73.2%	276.68%	-8.04%
Interest Paid ¹	-192	-1,299	-1,295	-1,232	-1,166	-1,901	-1,875	-1,713
Earnings before Tax (EBT) ¹	4,975	-6,871	8,098	7,713	8,440	-6,033	10,286	10,159
Change	-	-	-	-4.75%	9.43%	-	-	-1.24%
Net income ¹	3,439	-9,015	6,994	6,327	8,025	-3,489	11,492	11,288
Change	-	-	-	-9.54%	26.84%	-	-	-1.77%
Announcement Date	2/6/20	2/4/21	2/4/22	2/2/23	2/2/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2019 Q3	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	6,007	7,945	10,781	10,129	10,540	11,068	11,073	11,703	11,624	11,985	11,648	11,887	11,218	11,406	11,337	11,226	10,966	11,477	11,865	12,201	11,245	11,473	11,970	12,259	11,671	12,060
Change	-	32.26%	35.7%	-6.05%	4.06%	5.01%	0.05%	5.69%	-0.68%	3.11%	-2.81%	2.05%	-5.63%	1.68%	-0.6%	-0.98%	-2.32%	4.66%	3.38%	2.83%	-7.83%	2.02%	4.33%	2.42%	-4.79%	3.33%
EBITDA ¹	1,973	3,720	4,937	4,542	4,685	3,980	4,913	5,363	5,385	4,832	5,305	7,812	7,424	4,288	5,030	4,268	4,539	3,816	-8,984	7,477	3,974	4,191	-	-	-	-
Change	-	88.55%	32.72%	-8%	3.15%	-15.05%	23.44%	9.16%	0.41%	-10.27%	9.79%	47.26%	-4.97%	-42.24%	17.3%	-15.15%	6.35%	-15.93%	-	-	-46.85%	5.47%	-100%	-	-	-
EBIT ¹	1,802	2,484	4,716	4,373	4,521	3,816	4,758	5,198	5,204	4,670	5,267	5,229	4,836	4,110	4,857	4,251	4,360	3,630	-8,329	4,881	3,968	3,940	4,863	5,168	4,090	4,127
Change	-	37.85%	89.86%	-7.27%	3.38%	-15.59%	24.69%	9.25%	0.12%	-10.26%	12.78%	-0.72%	-7.52%	-15.01%	18.18%	-12.48%	2.56%	-16.74%	-	-	-18.7%	-0.72%	23.44%	6.28%	-20.86%	0.9%
Charge d'intérêts ¹	-36	-163	-301	-332	-333	-333	-344	-318	-316	-317	-316	-286	-299	-294	-288	-282	-280	-316	-425	-521	-506.3	-504.7	-	-	-	-
Earnings before Tax (EBT) ¹	-	-	-	1,627	-	-	-	-	-	-	-	1,958	2,209	1,859	2,770	1,859	2,137	1,674	-11,516	1,286	1,768	1,830	-	-	-	-
Change	-	-	-	-	-100%	-	-	-	-	-	-	-	12.82%	-15.84%	49%	-32.89%	14.95%	-21.67%	-	-	37.48%	3.51%	-100%	-	-	-
Net income ¹	1,353	-1,056	-	-85	1,872	-10,027	-	-	-	2,372	1,278	1,421	1,606	2,022	2,262	2,073	1,928	1,762	-11,911	1,680	1,393	2,275	-	-	-	-
Change	-	-	-100%	-	-	-	-100%	-	-	-	-46.12%	11.19%	13.02%	25.9%	11.87%	-8.36%	-6.99%	-8.61%	-	-	-17.09%	63.31%	-100%	-	-	-
Announcement Date	10/31/19	2/6/20	5/7/20	8/6/20	11/5/20	2/4/21	4/29/21	7/28/21	10/27/21	2/4/22	4/29/22	7/27/22	10/25/22	2/2/23	4/27/23	7/27/23	10/26/23	2/2/24	4/25/24	7/26/24	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Bristol-Myers Squibb Company

balance-sheet-analysis-chart BRISTOL-MYERS-SQUIBB-COMP

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	31,340	34,412	27,587	30,067	27,128	38,735	31,424	25,434
Change	-	9.8%	-19.83%	8.99%	-9.77%	42.79%	-18.87%	-19.06%
Announcement Date	2/6/20	2/4/21	2/4/22	2/2/23	2/2/24	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Bristol-Myers Squibb Company

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
CAPEX ¹	836	753	973	1,118	1,209	1,213	1,187	1,043
Change	-	-9.93%	29.22%	14.9%	8.14%	0.36%	-2.19%	-12.07%
Free Cash Flow (FCF) ¹	7,231	13,299	15,234	11,948	12,651	16,479	15,262	13,768
Change	-	83.92%	14.55%	-21.57%	5.88%	30.26%	-7.39%	-9.79%
Announcement Date	2/6/20	2/4/21	2/4/22	2/2/23	2/2/24	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Bristol-Myers Squibb Company

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	38.04%	42.61%	44.18%	43.59%	38.88%	10.84%	38.58%	35.96%
EBIT Margin (%)	31.36%	40.98%	42.75%	42.12%	37.3%	9.62%	36.44%	35.36%
EBT Margin (%)	19.03%	-16.16%	17.46%	16.71%	18.75%	-12.9%	22.12%	23.06%
Net margin (%)	13.15%	-21.2%	15.08%	13.71%	17.83%	-7.46%	24.71%	25.62%
FCF margin (%)	27.66%	31.28%	32.84%	25.88%	28.11%	35.24%	32.82%	31.25%
FCF / Net Income (%)	210.26%	-147.52%	217.82%	188.84%	157.64%	-472.29%	132.81%	121.97%
Profitability
ROA	-	11.89%	14.8%	16.04%	8.36%	-5.13%	11.57%	11.13%
ROE	24.49%	33.04%	45.69%	49.35%	51.57%	5.45%	75.26%	60.51%
Financial Health
Leverage (Debt/EBITDA)	3.15x	1.9x	1.35x	1.49x	1.55x	7.64x	1.75x	1.61x
Debt / Free cash flow	4.33x	2.59x	1.81x	2.52x	2.14x	2.35x	2.06x	1.85x
Capital Intensity
CAPEX / Current Assets (%)	3.2%	1.77%	2.1%	2.42%	2.69%	2.59%	2.55%	2.37%
CAPEX / EBITDA (%)	8.41%	4.16%	4.75%	5.56%	6.91%	23.94%	6.62%	6.59%
CAPEX / FCF (%)	11.56%	5.66%	6.39%	9.36%	9.56%	7.36%	7.78%	7.58%
Items per share
Cash flow per share ¹	4.712	6.223	7.297	6.089	6.67	9.75	8.326	7.34
Change	-	32.07%	17.26%	-16.56%	9.54%	46.18%	-14.61%	-11.83%
Dividend per Share ¹	1.68	1.84	2.01	2.19	2.31	2.391	2.504	2.553
Change	-	9.52%	9.24%	8.96%	5.48%	3.49%	4.74%	1.95%
Book Value Per Share ¹	30.26	16.75	16.7	14.34	14.73	10.12	11.98	13.4
Change	-	-44.65%	-0.33%	-14.11%	2.72%	-31.27%	18.29%	11.88%
EPS ¹	-	-3.99	3.12	2.95	3.86	-2.043	5.833	5.524
Change	-	-	-178.2%	-5.45%	30.85%	-152.93%	-385.49%	-5.29%
Nbr of stocks (in thousands)	2,344,185	2,259,752	2,219,645	2,219,645	2,034,758	2,027,395	2,027,395	2,027,395
Announcement Date	2/6/20	2/4/21	2/4/22	2/2/23	2/2/24	-	-	-